'MEDYED Clinic: Leading the Way in Aesthetic Medicine with Innovation, Safety, and Excellence'
- Advertisement -
In an inspiring journey of growth and innovation, this can summarize the story of MEDYED Clinic that transitioned from an educational training facility to a premier aesthetic and wellness clinic. This transformation not only highlights their dedication to advancing beauty and well-being but also marks a significant milestone in their commitment to patient-centered care and global excellence.
MEDYED Clinic has evolved from a training center to a full-service beauty and wellness clinic. This big step shows how dedicated they are to expanding their services and focusing on patients.
Shifting from education to direct patient care presented challenges, including expanding from a single treatment room to a multi-room clinic, recruiting highly skilled professionals, and implementing rigorous quality assurance protocols.
'Our new client-friendly environment ensures a warm, welcoming atmosphere with a well-organized patient management system' says the owners.
MEDYED Clinic has strengthened its presence by developing a comprehensive marketing strategy, an enhanced online platform featuring service details, online bookings. 'We have also curated a powerful brand image, with Maya Reaidy—whose medical background and beauty embody our values—as our brand ambassador. We prioritize personalized care through expert assessments and customized treatment plans, ensuring treatments align with patients' lifestyles and expectations. Regular follow-ups and feedback loops maintain our high standards of care, reinforcing our commitment to patient satisfaction.' Adds Charbel Rizk the founder.
Lebanon's reputation in beauty and wellness inspires MEDYED Clinic to collaborate with international experts and introduce advanced, FDA and CE-approved treatments. Through global partnerships, the clinic brings cutting-edge techniques while supporting local professionals in the aesthetic field. While adopting new technologies, MEDYED Clinic upholds strict ethical standards, ensuring treatments are both trendy and evidence-based. Their approach respects local beauty ideals, engaging communities to tailor services that resonate with diverse cultural preferences.
MEDYED Clinic is expanding beyond Lebanon, with branches in Cyprus, Qatar, and Jordan. Their vision includes introducing regenerative medicine, stem cell therapies, and mindfulness programs. They are particularly committed to well-being programs for pregnant women, promoting holistic health for mothers and future generations.
At MEDYED Clinic, a new era in aesthetic medicine is beginning, balancing innovation, safety, and excellence in patient care.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
12 minutes ago
- Business Upturn
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders
Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today announced that it has entered into a resolution agreement (the 'Resolution Agreement') with Goodwood Inc., Goodwood Fund and Puccetti Funds Management Inc. (collectively, 'Goodwood') to resolve matters relating to the upcoming annual and special meeting of COSCIENS' shareholders that had been scheduled to be held on June 26, 2025 (the '2025 Annual Meeting'). Pursuant to the Resolution Agreement, COSCIENS has today implemented a consensual reconstitution of its board of directors designed to best position COSCIENS to create value for all its shareholders. As a result of that reconstitution, COSCIENS' board of directors now consists of the following six directors: Anthony J. Giovinazzo, Ulrich Kosciessa, Ronald W. Miller, Peter H. Puccetti, Robert A. Seager and David Spear (the 'Reconstituted Board'). To facilitate the timely dissemination of COSCIENS' management information circular for the 2025 Annual Meeting, the meeting date has been postponed for several days and the 2025 Annual Meeting will now occur on June 30, 2025. At the 2025 Annual Meeting, COSCIENS will nominate for re-election as directors the six individuals who are now serving on the Reconstituted Board (and no other nominees). Goodwood has agreed that it will vote all of the 257,257 common shares of COSCIENS, or approximately 8.2% of COSCIENS' outstanding common shares, beneficially owned, or controlled or directed, directly or indirectly, by Goodwood in favour of the re-election of these six directors at the 2025 Annual Meeting. COSCIENS expects to disseminate its management information circular for the 2025 Annual Meeting within the next week. The Reconstituted Board is committed to ensuring that COSCIENS benefits from strong corporate governance and effective board oversight and doing what is in the best interests of COSCIENS and all of its shareholders. As part of that, the Reconstituted Board intends to actively review COSCIENS' prospects and opportunities, and to take the actions necessary to best position COSCIENS to create value for shareholders. Mr. Puccetti has been appointed as Chair of the Reconstituted Board. The Audit Committee now consists of Mr. Spear (Committee Chair), Mr. Kosciessa and Mr. Puccetti. The Human Resources, Nominating and Governance Committee now consists of Mr. Seager (Committee Chair), Mr. Miller and Mr. Giovinazzo. COSCIENS thanks each of its outgoing directors for their service to COSCIENS and acknowledges the contributions they have made to position COSCIENS for success. Details regarding each of the directors of COSCIENS now comprising the Reconstituted Board, each of whom will be nominated for re-election at the 2025 Annual Meeting, are set forth below: Anthony J. Giovinazzo Anthony Giovinazzo has over 45 years of executive experience and is an internationally recognized expert in intellectual property, drug development and commercialization, including numerous licensing agreements, with more than 25 years experience in Central Nervous System diseases. From 2009 until 2017, Mr. Giovinazzo served as the President and Chief Executive Officer of NASDAQ-listed Cynapsus Therapeutics Inc., a specialty pharmaceutical company that developed the first successful sublingual apomorphine thin film strip for Parkinson's disease. The drug was approved for commercialisation by the United States Food and Drug Administration in 2020. Mr. Giovinazzo was a co-inventor of the drug, built Cynapsus' leadership team, and was instrumental in its strategy including its over-subscribed IPO and NASDAQ listing. Mr. Giovinazzo became a director of Cynapsus in 2012. During Mr. Giovinazzo's tenure, Cynapsus attracted the top tier of institutional and venture capital funds in the United States. Mr. Giovinazzo led the negotiations with several pharmaceutical companies that resulted in the Cdn. $841 million all-cash acquisition of Cynapsus by Sunovion Pharmaceuticals (Dainippon Sumitomo Pharmaceuticals) in 2021 (at a 120% premium to Cynapsus' closing price on the day of announcement). From April 2006 to November 2009, Mr. Giovinazzo served as the Chief Executive Officer of Cervelo Pharmaceuticals Inc., a biopharmaceutical company. From 2002 to 2006, he served as Chief Executive Officer of Cita NeuroPharmaceuticals Inc., a biopharmaceutical company. Mr. Giovinazzo is currently a director of TSXV-listed Conavi Medical Inc., a commercial stage medical device company focused on designing, manufacturing and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. He is also currently the Chair of the Board of TSXV-listed Xortx Therapeutics Inc., a Phase 3 kidney and NDA pending Gout disease company. In 2014, Mr. Giovinazzo was a Canadian finalist in Life Sciences for the E&Y Entrepreneur of the Year. In 2017, he was the recipient of the Finance Monthly Game Changers award as well as the inaugural recipient of the Bloom Burton Award, which honors the best of the best in Canadian Life Sciences as judged by a panel of US experts. Mr. Giovinazzo has completed the Leadership and Strategy in Pharmaceuticals and Biotech from Harvard Business School. Mr. Giovinazzo also holds a Masters of Business Administration from IMD, Geneva Switzerland, a Graduate Certificate Studies in Canadian Law from Osgoode Hall Law School at York University, and a Bachelor of Arts in Economics and Accounting from McMaster University. Ulrich Kosciessa Dr. Kosciessa currently serves as the Chief Executive Officer of Germany-based Photonamic GmbH & Co. KG and as the Chief Operating Officer of Tokyo-based SBI Pharmaceuticals Co. LTD. He has worked for 20 years for Medac GmbH, a global pharmaceutical company with operations in 70 countries where he served as a member of the Executive Management Board, as Managing Director of Medac International and as Chairman of the Board of Medac Pharma Inc., a U.S.-based subsidiary of Medac GmbH focused on specialty pharmaceuticals for autoimmune diseases and cancer. Throughout his career at Medac, Dr. Kosciessa has formed several subsidiaries and affiliates as well as established a network of global partners, growing the Company's international business more than 50% since 2005. In addition, since 2006 Dr. Kosciessa has also served as Chief Executive Officer of Photonamic, a subsidiary of Medac GmbH focused on research and development of photodynamic therapy and diagnostics. He has successfully developed two Photonamic products currently marketed in Europe, North America, South America, the Asian Pacific region and Australia. From 2006 to 2008, Dr. Kosciessa served as Chief Executive Officer at Immune Laboratory of Hannover, a research-based organization focused on autologous dendritic cell-based tumor vaccines. Prior to joining Medac GmbH, Dr. Kosciessa was a postdoctoral researcher at the neuroscience/neurodegenerative diseases division of Schering AG, a multinational pharmaceutical company. He received a in Biology and a Ph.D. in Molecular Biology from Georg-August University of Göttingen, Germany. Ronald W. Miller Ronnie Miller was President and CEO of Hoffmann-La Roche Limited (Roche Canada) for 22 years (until 2022). In this role, he was responsible for the growth and success of the Canadian Pharmaceuticals Division, particularly as it relates to Roche's mandate of developing and delivering innovative healthcare solutions for Canadians. Ronnie has more than 43 years of extensive and varied experience in the pharmaceutical industry. Born in Scotland, Mr. Miller completed his Bachelor of Science in Economics and Geography at the University of Glasgow, then moved to Leeds, England to accept a job as a pharmaceutical sales representative. Mr. Miller advanced through a series of successive sales and management positions across the industry to become the National Sales Manager for Roche in the United Kingdom in 1988 and continued to move globally as a Product Manager in Switzerland and Deputy Divisional Director of the Pharmaceutical Division in Japan. He moved back to Switzerland to head up a global product launch before returning to the UK as Pharmaceuticals Director. Mr. Miller was appointed President and CEO of Roche Pharmaceuticals in Canada in May 2000 and became a Canadian citizen in 2008. Mr. Miller was re-elected as Chairman of the Board of Directors of Innovative Medicines Canada (IMC), the national association representing Canada's research-based pharmaceutical companies, from 2019 to 2022. He served as Chairman of the IMC Board in 2007 and has since fulfilled two subsequent terms as Past Chair. Prior to this, Mr. Miller was the Chair of the IMC Prairies Core Team and sat as Co-Chair of the Health Research Foundation. He also served on several committees including the IMC Public Affairs, Stakeholder Relations, the British Columbia Sub-Committee, and was Chair of the Federal Affairs/FPT Relations Standing Committee. Peter H. Puccetti Peter Puccetti is the founder, Chairman and Chief Investment Officer of Goodwood Inc., a Canadian independent investment management firm that has provided institutional and high-net-worth clients with alternative investment strategies for over 28 years. Mr. Puccetti has managed the flagship Goodwood Fund since its inception, and has over 30 years of investment experience with a focus on special situations value investing. Mr. Puccetti has served on a number of public and private boards of directors. Mr. Puccetti and Goodwood Inc. have become well-known in Canada for leading a variety of activist campaigns to implement positive change and unlock shareholder value with the trust and support of many of Canada's top institutional investment organizations. Prior to founding Goodwood Inc., Mr. Puccetti was an analyst, investment banker and partner of Sprott Securities Limited. Mr. Puccetti holds a Bachelor of Arts in Economics from Dalhousie University. Mr. Puccetti is also a CFA Charterholder. Robert A. Seager Robert Seager is a leading special situations advisor and has been centrally involved in directing high profile shareholder disputes, proxy contests, M&A transactions, special committee mandates, internal and independent corporate investigations and complex restructurings. Mr. Seager is a trusted strategic advisor to institutional and other significant stakeholders, boards of directors and executive management teams with respect to corporate governance matters involving both public and private companies, including providing guidance through crisis situations and critical opportunities. Mr. Seager is a Partner of Voorheis & Co. LLP and Executive Vice President, Seacombe Partners Inc. In 2023, Mr. Seager was appointed to the Securities Advisory Committee of the Ontario Securities Commission (OSC). This committee, comprised of leading securities practitioners and other industry experts, plays a crucial role in advising the OSC and its staff on a variety of matters including policy initiatives and capital markets trends. Prior to joining Voorheis & Co. LLP in 2017, Mr. Seager practiced securities law at Blake, Cassels & Graydon LLP, and completed a secondment with the Office of M&A at the OSC. Mr. Seager received his J.D. from the Schulich School of Law at Dalhousie University with a specialization in corporate law, his International Business Law Certification from the Global Law Program at the Bader International Study Centre, and his Bachelor of Commerce from the Sauder School of Business at the University of British Columbia. Rob has also completed Levels 1 and II of the CFA Program. David Spear David Spear is an accomplished entrepreneur and executive with more than 35 years of experience in the healthcare industry, with a particular focus on the eyecare sector. Mr. Spear is currently the President and Chief Strategy Officer of Advancing Eyecare, a partnership of leaders in the eyecare instrumentation marketplace established to offer the best products and service solutions in the ophthalmic equipment industry. Mr. Spear previously served as a director of Innova Medical Ophthalmics, a supplier to the Canadian ophthalmic community that he co-founded in 1987. Mr. Spear also previously served as a director of Advancing Eyecare from 2017 to 2023. Throughout his career, Mr. Spear has played a pivotal role in launching and leading multiple ventures within the ophthalmic and medical device industries. His entrepreneurial journey includes co-founding and managing S4OPTIK LLC, Blue.S4 Precision Manufacturing, Innovative Excimer Solutions, and S4OPTIK S.A. de C.V. in Mexico. Mr. Spear holds a Bachelor of Commerce from the University of Windsor and a Bachelor of Science in Biology from Western University. A copy of the Resolution Agreement will be made available on COSCIENS' profile on SEDAR+ at in due course. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements. All statements contained in this filing that are not clearly historical in nature or that necessarily depend on future events are forward-looking, and the words 'intends,' 'expects,' and similar expressions are generally intended to identify forward-looking statements. These statements are based on current expectations of COSCIENS and Goodwood and currently available information. They are not guarantees of future performance, involve certain risks and uncertainties that are difficult to predict, and are based upon assumptions as to future events that may not prove to be accurate. Neither COSCIENS nor Goodwood assume any obligation to update any forward-looking statements contained in this press release, except as required by applicable law. For further information contact: Peter H. PuccettiChairman of the BoardCOSCIENS Biopharma Inc. Tel: 416-203-2722 Email: [email protected]
Business Upturn
12 minutes ago
- Business Upturn
Momcozy MaxSupport Nursing Pillow: Easier Nursing with Certified Safety and Ergonomic Design
New York, NY, May 30, 2025 (GLOBE NEWSWIRE) — Momcozy, a global maternity care brand known for its innovation and dedication to maternal wellness, introduces the MaxSupport Nursing Pillow collection —an ergonomic, memory foam-based system designed to enhance comfort and safety for breastfeeding mothers. This launch is part of Momcozy's mission to make healthier, easier nursing a reality for every parent. Firm Support with Memory Foam Comfort At the heart of every MaxSupport pillow is 45D high-density memory foam, selected for its ability to gently contour to the body while retaining structure. Unlike traditional fiber-filled pillows that lose shape over time, MaxSupport offers a resilient foundation that feels like resting on a mini high-quality mattress. Its 28% wider surface provides enhanced arm and upper-body support—minimizing shoulder tension and promoting natural feeding alignment, especially during extended sessions. Certified Safety That Meets 2024 Federal Standards In response to the 2024 CPSC safety regulations, the MaxSupport Nursing Pillow is fully engineered to meet the latest U.S. federal safety standards. The pillow's certified firmness, safe feeding angles, and protective side barrier are designed to reduce the risks of suffocation and falls—giving moms peace of mind during every feeding. All MaxSupport models are made with CertiPUR-US® certified memory foam and OEKO-TEX® certified fabrics, ensuring the materials are non-toxic, skin-friendly, and safe for babies and mothers alike. Built-In Safety Features for Confident Nursing A softly contoured side safety fence surrounds the nursing area to help secure the baby in place, reducing the chance of rolling or slipping. This, combined with the adjustable height options and removable waist and arm support cushions, allows for full customization based on body type, feeding position, or postpartum recovery needs. These ergonomic enhancements are designed to reduce back and neck strain, support better latching, and help alleviate common breastfeeding discomforts like nipple soreness due to poor positioning. Two Models, One Purpose: Better Breastfeeding Support The MaxSupport collection includes two tailored versions: Momcozy Original MaxSupport Nursing Pillow – Essential Set ($54.99) CozyPro MaxSupport Nursing Pillow – Upgraded Set ($69.99) The Essential Set features all core ergonomic and safety innovations, while the CozyPro version includes enhanced premium fabric finishes for moms seeking a touch of elevated comfort and style. Both models are built to retain their shape over time, making them ideal for long-term, daily use. Designed by Moms, Backed by Experts The MaxSupport line was developed through real insights from mothers and professional feedback from healthcare advisors. Whether used during cluster feeding, nighttime nursing, twin feeding, or bottle support, the pillows are crafted to adapt to real-life parenting scenarios. Momcozy's thoughtful design ensures that support doesn't fade over time, but continues to deliver relief, alignment, and comfort through each stage of the breastfeeding journey. Comfort Is Care: A Brand Mission in Action The launch of the MaxSupport Nursing Pillow reflects Momcozy's broader commitment to supporting parents through intuitive, functional, and medically informed maternity products. Alongside its popular wearable breast pumps, maternity apparel, and wellness tools, MaxSupport underscores the brand's belief that comfort is a form of care—and every mother deserves both. Exclusively available at , the MaxSupport Nursing Pillow is more than a feeding accessory—it's a trusted daily companion for healthier breastfeeding, safer positioning, and an all-around better experience. #MomcozyMaxSupportNursingPillow #MaxSupportNursingPillow #CertifiedComfortForMoms
Business Upturn
12 minutes ago
- Business Upturn
Best Therapists Hong Kong – Maple Tree Counselling Launch Professional Psychotherapy Practice in HK
Central, May 30, 2025 (GLOBE NEWSWIRE) — Central, Hong Kong – Nestled in the bustling heart of Central, Hong Kong, Maple Tree Counselling continues to thrive in the landscape of mental healthcare with its dynamic, multicultural team and their expansive range of therapeutic services and modalities. As mental health awareness rises across Asia, this boutique practice has emerged as a leading light, offering deeply personalised support to individuals (adolescents and adults), couples, families, and corporations across Hong Kong. For more information, visit Founded with a mission to create a sanctuary for healing and personal growth, Maple Tree Counselling is rapidly becoming a household name among professionals, expats, and local residents alike. With a holistic approach grounded in empathy, clinical excellence, and cultural sensitivity, the practice delivers tailored therapy in English, Cantonese, and Mandarin, ensuring clients from diverse backgrounds feel seen, heard, and supported. For anyone wondering if they should go for therapy, a spokesperson from Maple Tree Counselling suggests, 'Anyone can benefit from therapy whether they are currently in crisis or embarking on a journey of self-exploration or change. You may want to better understand your past in order to move forward, change old patterns, heal from past trauma, improve relationships or move bravely into uncharted territory. These are some of the issues we regularly explore with clients. If any of these resonate with you or if you have any questions about whether our practice is right for you, please get in touch, and we will be happy to engage with you directly.' Maple Tree Counselling offers a full spectrum of services designed to meet the evolving needs of its clients. From one-on-one psychotherapy for adults and adolescents, to relationship-focused counselling for couples and families, each session is conducted with the highest ethical standards and a client-centered philosophy. The practice's team of therapists hail from a variety of cultural and professional backgrounds, with training in CBT (Cognitive Behavioral Therapy), EMDR (Eye Movement Desensitization and Reprocessing), ACT (Acceptance and Commitment Therapy) mindfulness, and schema therapy. This rich range of modalities enables Maple Tree to provide nuanced support that resonates with Hong Kong's cosmopolitan population. In addition to individual and group therapy, Maple Tree Counselling has rapidly expanded its corporate wellness programmes, partnering with companies across the finance, tech, law, and education sectors. Services include on-site counselling, mental health check-ins, tailored workshops, and psychoeducational webinars designed to foster emotionally intelligent and resilient workplaces. As Hong Kong's high pressure work culture continues to take a toll on employee well-being, Maple Tree's proactive approach is gaining traction. What sets Maple Tree Counselling apart is its practitioners' unwavering commitment to quality, confidentiality, and innovation. Whether helping an executive navigate burnout, guiding a teenager through academic stress, or facilitating family reconciliation, the team operates with the utmost professionalism and care. This reputation for excellence has not gone unnoticed. Maple Tree has been featured in several leading mental health publications and is frequently cited as one of Hong Kong's top therapy practices. With demand continuing to surge, the practice is actively recruiting additional therapists to meet client needs without compromising on its boutique ethos. Clients consistently praise Maple Tree for its warmth, accessibility, and life-changing results. The practice's success is a testament not only to the expertise of its counsellors, but also to a growing cultural shift: one that recognises therapy as a courageous, empowering step toward a better life. With a flourishing practice and a purpose-driven mission, Maple Tree Counselling is not just responding to the city's mental health needs, it's shaping the future of emotional well-being in Hong Kong. Those interested in learning more about Maple Tree Counselling's services, including therapy for individuals, couples, and families, as well as corporate well-being solutions, can visit the official website at or contact the team via phone or email to schedule a confidential consultation. ### For more information about Maple Tree Counselling, contact the company here: Maple Tree CounsellingAnjali Nihalchand+852 6375 6098 [email protected] 19th Floor, China Building, 29 Queen's Road Central, Central, Hong Kong
